{
  "extraction_metadata": {
    "extraction_date": "2025-08-08 02:53:51",
    "total_papers_processed": 29,
    "note": "All data includes direct quotes and source locations for verification"
  },
  "azacitidine": [
    {
      "complete_response": 12.5,
      "partial_response": null,
      "marrow_complete_response": 50,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Short Nicholas J, Muftuoglu Muharrem, Ong Faustine et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of hematology & oncology (2023)",
      "pmid": "37422688",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
      "cmml_sample_size": 8,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "In the CMML cohort, the overall response rate was 75% (CR 12.5%; mCR with or without HI 50%; HI 12.5%).  Seven of eight patients (87%) were high or very high risk by the IPSS-R.",
      "study_design": "Phase 1/2",
      "patient_population": "Older adults with CMML after failure of hypomethylating agents.",
      "treatment_details": "Azacitidine 75 mg/m\u00b2, venetoclax, and pevonedistat.  Specific dosing and scheduling for venetoclax and pevonedistat are not detailed in the provided abstract.",
      "supporting_quotes": [
        "In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R.",
        "The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%)."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 37422688 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/37422688/"
    },
    {
      "complete_response": 7,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Tefferi Ayalew Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American journal of hematology (2022)",
      "pmid": "34985762",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Hypomethylating agents (5-azacitidine and decitabine) show overall response rates of ~40-50% and complete remission rates of ~7-17% in CMML. Allogeneic stem cell transplant is the only potentially curative option.",
      "study_design": "Review Article",
      "patient_population": "Patients with CMML.",
      "treatment_details": "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used.",
      "supporting_quotes": [
        "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens.",
        "Allogeneic stem cell transplant is the only potentially curative option but is associated with significant morbidity and mortality."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 34985762 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/34985762/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 36,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Lasho Terra Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology. American Society of Hematology. Education Program (2020)",
      "pmid": "33275673",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "CMML is the most frequent MDS/MPN overlap neoplasm, with a median overall survival of <36 months.  Adverse prognostic factors include increasing age, high WBC, circulating immature myeloid cells, anemia, thrombocytopenia, and truncating ASXL1 mutations. Hypomethylating agents (azacitidine, decitabine, oral decitabine/cedazuridine) have overall response rates of 40-50% and complete remission rates of <20%.",
      "study_design": "Review Article",
      "patient_population": "CMML patients, predominantly presenting in the 7th decade of life with male preponderance.",
      "treatment_details": "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML.",
      "supporting_quotes": [
        "CMML usually presents in the 7th decade of life, with a male preponderance and is associated with a median overall survival of <36 months.",
        "Adverse prognosticators in CMML include increasing age, high WBC, presence of circulating immature myeloid cells, anemia, thrombocytopenia and truncating ASXL1 mutations.",
        "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML, with overall response rates of 40-50% and complete remission rates of <20%."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33275673 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33275673/"
    },
    {
      "complete_response": 22,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Pleyer Lisa, Germing Ulrich, Sperr Wolfgang R et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia research (2014)",
      "pmid": "24522248",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24522248/",
      "cmml_sample_size": 48,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Azacitidine showed a trend towards improved two-year survival compared to best supportive care (62% vs 41%, p=0.067) and longer OS when used first-line compared to hydroxyurea first-line (p=0.072, median OS 27.7 vs 6.2 months). Overall response rate was 70% (including 22% complete responses). Monocyte count and cytogenetics affected survival, but age, WHO-type, FAB-type, and spleen size did not.",
      "study_design": "Matched-pair analysis",
      "patient_population": "48 CMML patients treated with azacitidine.  The abstract does not provide further details on patient characteristics.",
      "treatment_details": "The abstract does not specify azacitidine dosing, schedule, or whether it was used in combination with other therapies.",
      "supporting_quotes": [
        "Overall response rates were high (70% according to IWG-criteria, including 22% complete responses).",
        "Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months)."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 24522248 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/24522248/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "M\u0105dry Krzysztof, Lis Karol, Sienkiewicz Elzbieta et al. No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group. Frontiers in oncology (2024)",
      "pmid": "38939343",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38939343/",
      "cmml_sample_size": 22,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The study included CMML patients treated with azacitidine, but did not report CMML-specific efficacy outcomes such as response rates or survival data.  Infection data was collected for all patients, including the CMML subset.",
      "study_design": "prospective non-intervention study",
      "patient_population": "22 CMML patients (7.1% of the total cohort of 307 patients) treated with azacitidine.  Median age at treatment commencement was 71 years (range, 18-95).",
      "treatment_details": "Azacitidine treatment.  Antibacterial, antifungal, and antiviral prophylaxis was used in 66.0%, 29.3%, and 25.7% of patients, respectively.",
      "supporting_quotes": [
        "We collected data on 307 patients, 57.6 % males, treated with azacitidine: AML (37.8%), MDS (55.0%), and CMML (7.1%).",
        "The median age at azacitidine treatment commencement was 71 (range, 18-95) years.",
        "Antibacterial, antifungal, and antiviral prophylaxis was used in 66.0%, 29.3%, and 25.7% of patients, respectively."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 38939343 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/38939343/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Kunacheewa Chutima, Thongthang Pakaporn, Ungprasert Patompong et al. A systematic review and meta Hematology (Amsterdam, Netherlands) (2019)",
      "pmid": "31221030",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31221030/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The meta-analysis included CMML patients treated with azacitidine plus lenalidomide, but did not report CMML-specific outcomes separately from AML and high-risk MDS patients.  The overall pooled complete remission (CR) rate across all three disease types was 33%.",
      "study_design": "Meta-analysis",
      "patient_population": "Patients with high-risk MDS, AML, or CMML who received AZA in combination with LEN.",
      "treatment_details": "Azacitidine plus lenalidomide; specific dosing and scheduling not detailed in the provided abstract.",
      "supporting_quotes": [
        "The addition of lenalidomide (LEN) to azacitidine (AZA) may further improve the outcomes of acute myeloid leukemia (AML) patients as well as patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients although the evidence for this combination treatment is still relatively limited.",
        "The pooled CR rate after the treatment with AZA-plus-LEN regimen was 33.0% (95% CI, 27.7%-38.7%, I"
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 31221030 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/31221030/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Triguero A, Xicoy B, Zamora L et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Leukemia research (2022)",
      "pmid": "35405632",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35405632/",
      "cmml_sample_size": 91,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Overall response rate to azacitidine in CMML patients was 58% at cycles 4-6, using MDS/MPN response criteria.  Almost half achieved transfusion independence, and a quarter showed clinical benefit, regardless of CMML subtype or CPSS risk group. Toxicity was higher in the MD-CMML subtype.",
      "study_design": "retrospective",
      "patient_population": "91 patients with CMML treated with at least one cycle of azacitidine from the Spanish Registry of MDS.  The study included patients with various CMML FAB and WHO subtypes and CPSS risk groups.",
      "treatment_details": "At least one cycle of azacitidine. Response rate evaluated between cycle 4 and 6.",
      "supporting_quotes": [
        "The overall response rate at cycle 4-6 was 58%.",
        "Almost half of the patients achieved transfusion independence and one quarter showed clinical benefit, regardless of the CMML French-American-British (FAB) and World Health Organization (WHO) subtypes and CMML Specific Prognosis Scoring (CPSS) risk groups.",
        "Toxicity was higher in the MD-CMML subtype."
      ],
      "data_source_location": "Abstract and Findings section",
      "reference_note": "See PMID 35405632 - Abstract and Findings section",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/35405632/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Kantarjian Hagop, Borthakur Gautam, Daver Naval et al. Current status and research directions in acute myeloid leukemia. Blood cancer journal (2024)",
      "pmid": "39300079",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39300079/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Decitabine-cedazuridine (a fully absorbable decitabine formulation) is mentioned as approved for myelodysplastic syndrome and chronic myelomonocytic leukemia, and commonly used in AML.",
      "study_design": "Review Article",
      "patient_population": "The abstract does not specify a CMML patient cohort for any particular treatment.",
      "treatment_details": "The abstract only mentions that decitabine-cedazuridine is approved for MDS and CMML and commonly used in AML, without providing details on dosing, schedule, or combination therapies within the context of CMML.",
      "supporting_quotes": [
        "and two oral hypomethylating agents (oral poorly absorbable azacitidine; fully absorbable decitabine-cedazuridine [latter approved as an alternative to parenteral hypomethylating agents in myelodysplastic syndrome and chronic myelomonocytic leukemia but commonly used in AML]);"
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 39300079 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/39300079/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Islam Anwarul An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia. Clinical case reports (2023)",
      "pmid": "37546162",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
      "cmml_sample_size": 1,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "One patient with CMML experienced disease progression with a marked increase in leucocyte count during treatment with a conventional dose of intravenous azacitidine.  This is reported as the first such case in the literature.",
      "study_design": "case report",
      "patient_population": "A single patient with CMML.",
      "treatment_details": "Conventional dose of intravenous azacitidine.",
      "supporting_quotes": [
        "Our report describes a patient with CMML who not only did not respond to a conventional dose of intravenous (IV) therapy with AZA, but showed marked progression of the disease with the leucocyte count rising exponentially while undergoing the aforesaid treatment.",
        "We believe this is the first such case reported in the currently extant literature."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 37546162 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/37546162/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Wei Yue, Zheng Hong, Lockyer Pamela Pennington et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & lymphoma (2022)",
      "pmid": "36059252",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36059252/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The study investigated the combination of azacitidine with MDM2 antagonists in cellular and animal models of CMML, but did not report specific clinical outcomes in CMML patients.",
      "study_design": "Preclinical (cellular and animal models)",
      "patient_population": "The abstract mentions using cellular and animal models of CMML, but provides no details on human patient characteristics.",
      "treatment_details": "The study investigated the combination of azacitidine with DS-3032b and DS-5272, novel MDM2 antagonists, in cellular and animal models.",
      "supporting_quotes": [
        "We investigated the combination of the HMA azacitidine (AZA) with DS-3032b and DS-5272, novel antagonists of the TP53 negative regulator MDM2, in cellular and animal models of MDS and CMML."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 36059252 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/36059252/"
    }
  ],
  "decitabine": [
    {
      "complete_response": 7,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Tefferi Ayalew Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American journal of hematology (2022)",
      "pmid": "34985762",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Hypomethylating agents (5-azacitidine and decitabine) show overall response rates of ~40-50% and complete remission rates of ~7-17% in CMML.  Allogeneic stem cell transplant is the only potentially curative option.",
      "study_design": "Review Article",
      "patient_population": "Patients with Chronic Myelomonocytic Leukemia (CMML)",
      "treatment_details": "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used.",
      "supporting_quotes": [
        "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens.",
        "Allogeneic stem cell transplant is the only potentially curative option but is associated with significant morbidity and mortality."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 34985762 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/34985762/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 36,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patnaik Mrinal M, Lasho Terra Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology. American Society of Hematology. Education Program (2020)",
      "pmid": "33275673",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "CMML is the most frequent MDS/MPN overlap neoplasm, with a median overall survival of <36 months.  Adverse prognostic factors include increasing age, high WBC, circulating immature myeloid cells, anemia, thrombocytopenia, and truncating ASXL1 mutations. Hypomethylating agents (azacitidine, decitabine, oral decitabine/cedazuridine) have overall response rates of 40-50% and complete remission rates of <20%.",
      "study_design": "Review Article",
      "patient_population": "CMML patients, predominantly presenting in the 7th decade of life with male preponderance.",
      "treatment_details": "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML.",
      "supporting_quotes": [
        "CMML usually presents in the 7th decade of life, with a male preponderance and is associated with a median overall survival of <36 months.",
        "Adverse prognosticators in CMML include increasing age, high WBC, presence of circulating immature myeloid cells, anemia, thrombocytopenia and truncating ASXL1 mutations.",
        "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML, with overall response rates of 40-50% and complete remission rates of <20%."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33275673 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33275673/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Garcia-Manero Guillermo, Griffiths Elizabeth A, Steensma David P et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood (2020)",
      "pmid": "32285126",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The study included patients with CMML, but did not report CMML-specific outcomes separately from MDS patients.  Overall clinical responses were observed in 60% of patients (including 21% with complete response), but this is not broken down by CMML vs MDS.",
      "study_design": "Phase 2 randomized crossover study",
      "patient_population": "Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)",
      "treatment_details": "Oral cedazuridine/decitabine (100/35 mg) compared to IV decitabine 20 mg/m2.  Initially given as separate capsules, then as a single fixed-dose combination (FDC) tablet.",
      "supporting_quotes": [
        "Adults with International Prognostic Scoring System intermediate-1/2- or high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) were randomized 1:1 to receive oral cedazuridine/decitabine or IV decitabine in cycle 1, followed by crossover to the other treatment in cycle 2.",
        "Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 32285126 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/32285126/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Itzykson Raphael, Santini Valeria, Thepot Sylvain et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)",
      "pmid": "36455187",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
      "cmml_sample_size": 170,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Frontline treatment with decitabine did not improve event-free survival (EFS) compared to hydroxyurea in patients with advanced myeloproliferative CMML.",
      "study_design": "Randomized Phase III Trial",
      "patient_population": "Newly diagnosed myeloproliferative CMML patients with advanced disease. Median age was 72 and 74 years, and median WBC count 32.5 \u00d7 10\u2079/L.",
      "treatment_details": "Patients were randomly assigned 1:1 to intravenous DAC (20 mg/m\u00b2) or HY.  Further details on dosing and schedule are not provided in the abstract.",
      "supporting_quotes": [
        "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
        "Median age was 72 and 74 years, and median WBC count 32.5 \u00d7 10\u2079/L.",
        "Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML"
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 36455187 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/36455187/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Patel Anand A, Cahill Kirk, Saygin Caner et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood advances (2021)",
      "pmid": "33904891",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33904891/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Phase 2 data confirmed bioequivalence of C-DEC when compared with parenteral decitabine, and a larger phase 3 trial has demonstrated similar results, leading to the FDA approval of C-DEC for use in ... CMML.",
      "study_design": "Phase 2 and Phase 3",
      "patient_population": "The abstract mentions that early-phase clinical trials of oral cedazuridine-decitabine (C-DEC) were conducted in  chronic myelomonocytic leukemia (CMML), and that the FDA approved C-DEC for use in CMML.  No further details on patient characteristics are provided.",
      "treatment_details": "A combination of oral decitabine 35 mg with oral cedazuridine 100 mg was established as the recommended phase 2 dose.",
      "supporting_quotes": [
        "A combination of oral decitabine 35 mg with oral cedazuridine 100 mg was established as the recommended phase 2 dose.",
        "Phase 2 data confirmed bioequivalence of C-DEC when compared with parenteral decitabine, and a larger phase 3 trial has demonstrated similar results, leading to the FDA approval of C-DEC for use in intermediate/high-risk myelodysplastic syndrome (MDS) and CMML."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33904891 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33904891/"
    },
    {
      "complete_response": 14,
      "partial_response": 11,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Wijermans P W, R\u00fcter B, Baer M R et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leukemia research (2008)",
      "pmid": "17881052",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
      "cmml_sample_size": 31,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Overall response rate (ORR) of 25% (14% CR + 11% PR) in 31 CMML patients treated with decitabine. Hematologic improvement in 11% and stable disease in 39%.  Adverse events similar to other hematologic populations.",
      "study_design": "Phase 2 and 3 trials",
      "patient_population": "31 patients diagnosed with CMML; average age 70.2 years, 71% male. Baseline WBC >20,000 in 29% and baseline bone marrow blasts >5% in 39%.",
      "treatment_details": "Decitabine; details on dosing and schedule not specified, data from three trials (one phase 3 and two phase 2) combined.",
      "supporting_quotes": [
        "The ORR was 25% (14% CR+11% PR).",
        "Hematologic improvement was observed in 11% of patients and stable disease in 39% of patients.",
        "A total of 31 patients diagnosed with CMML are included in this review.",
        "Similar demographics and disease characteristics were observed in all three studies, with an average age of 70.2 years and 71% of patients male. Baseline WBC of >20,000 were observed in 8/28 (29%) patients and baseline bone marrow blasts >5% in 11/28 (39%) patients."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 17881052 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/17881052/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Thota Swapna, Oganesian Aram, Azab Mohammad et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. Future oncology (London, England) (2021)",
      "pmid": "33709786",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33709786/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The review mentions the FDA approval of cedazuridine/decitabine for intermediate or high-risk MDS and CMML, but provides no specific CMML clinical outcome data.",
      "study_design": "Review",
      "patient_population": "Newly diagnosed or previously treated intermediate or high-risk (by international prognostic scoring system) CMML patients.",
      "treatment_details": "Oral fixed drug combination of decitabine and cedazuridine.",
      "supporting_quotes": [
        "This drug was recently approved by the US FDA, Australian TGA and Health Canada for newly diagnosed or previously treated intermediate or high risk by international prognostic scoring system, MDS and CMML."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33709786 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33709786/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Kantarjian Hagop, Borthakur Gautam, Daver Naval et al. Current status and research directions in acute myeloid leukemia. Blood cancer journal (2024)",
      "pmid": "39300079",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39300079/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Decitabine-cedazuridine (a fully absorbable decitabine formulation) is mentioned as approved for myelodysplastic syndrome and chronic myelomonocytic leukemia, and commonly used in AML.",
      "study_design": "Review Article",
      "patient_population": "The abstract does not specify a CMML patient cohort for any particular treatment.",
      "treatment_details": "The abstract only mentions that decitabine-cedazuridine is approved for MDS and CMML and commonly used in AML, without providing details on dosing, schedule, or combination therapies within the context of CMML.",
      "supporting_quotes": [
        "two oral hypomethylating agents (oral poorly absorbable azacitidine; fully absorbable decitabine-cedazuridine [latter approved as an alternative to parenteral hypomethylating agents in myelodysplastic syndrome and chronic myelomonocytic leukemia but commonly used in AML])"
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 39300079 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/39300079/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": 10.7,
      "os_median": 21.6,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Yun John Paul, Ding Philip Q, Dolley Aastha et al. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada. Current oncology (Toronto, Ont.) (2023)",
      "pmid": "37754496",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37754496/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The study reports median overall survival (OS) and progression-free survival (PFS) for patients with MDS and CMML treated with decitabine/cedazuridine.  Specific CMML-only outcomes are not broken down separately from MDS.",
      "study_design": "Real-world observational study",
      "patient_population": "769 patients enrolled in Taiho Pharma Canada's Patient Support Program from November 10, 2020, to August 31, 2022, with a median age of 76 years.  The exact number of CMML patients is not specified.",
      "treatment_details": "Decitabine/cedazuridine (DEC-C, ASTX727). Median treatment duration was 4.2 cycles.",
      "supporting_quotes": [
        "Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles.",
        "The median overall and progression-free survival were 21.6 and 10.7 months, respectively."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 37754496 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/37754496/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Sheel Ankur, Bae Junu, Asada Ashlee et al. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report. Cardio-oncology (London, England) (2023)",
      "pmid": "36653885",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36653885/",
      "cmml_sample_size": 1,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "One 85-year-old female with CMML developed reversible cardiomyopathy and heart failure after 5 cycles of decitabine/cedazuridine.  Cardiac function recovered after drug discontinuation.",
      "study_design": "case report",
      "patient_population": "One 85-year-old Caucasian female with CMML.",
      "treatment_details": "5 cycles of decitabine/cedazuridine.",
      "supporting_quotes": [
        "This case study presents an 85\u2009year-old\u00a0Caucasian\u00a0female with CMML who developed cardiomyopathy and heart failure with reduced ejection fraction after completing 5\u2009cycles of therapy with decitabine/cedazuridine.",
        "Furthermore, her symptoms and cardiac function recovered upon discontinuation of the drug."
      ],
      "data_source_location": "Abstract and Case sections",
      "reference_note": "See PMID 36653885 - Abstract and Case sections",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/36653885/"
    }
  ],
  "hydroxyurea": [
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Itzykson Raphael, Santini Valeria, Thepot Sylvain et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)",
      "pmid": "36455187",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
      "cmml_sample_size": 170,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Frontline treatment with decitabine did not improve event-free survival compared to hydroxyurea in patients with advanced myeloproliferative CMML.",
      "study_design": "Randomized Phase III Trial",
      "patient_population": "Newly diagnosed myeloproliferative CMML patients with advanced disease. Median age was 72 and 74 years, and median WBC count 32.5 \u00d7 10\u2079/L.",
      "treatment_details": "Patients were randomly assigned 1:1 to intravenous DAC (20 mg/m\u00b2) or HY.  Further details on dosing and schedule are not provided in the abstract.",
      "supporting_quotes": [
        "One-hundred seventy patients received DAC (n = 84) or HY (n = 86).",
        "Median age was 72 and 74 years, and median WBC count 32.5 \u00d7 10\u2079/L.",
        "Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML"
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 36455187 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/36455187/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Hu Lianbo, Zheng Bingrong, Fu Lijuan et al. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report. Medicine (2020)",
      "pmid": "33126392",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33126392/",
      "cmml_sample_size": 1,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Pleural effusion, the first manifestation of CMML-0 in a 44-year-old woman, resolved after treatment with azacitidine and hydroxyurea.",
      "study_design": "case report",
      "patient_population": "One 44-year-old woman with CMML-0 and pleural effusion as the first manifestation.",
      "treatment_details": "Azacitidine 75 mg/m\u00b2 daily for 2 cycles, followed by hydroxyurea 500 mg/day orally.",
      "supporting_quotes": [
        "The patient was treated with azacitidine 75\u200amg/m\u200ad for 2 cycles, followed by daily oral intake of hydroxyurea (500\u200amg/d).",
        "Pleural effusion was resolved and chest pain was relieved."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 33126392 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/33126392/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Strupp C, Germing U, Trommer I et al. Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leukemia research (2000)",
      "pmid": "11077120",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11077120/",
      "cmml_sample_size": 1,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Pericardial effusion is a rare but potentially life-threatening complication of CMML.  Treatment with pericardiocentesis and intracardial mitoxantrone showed poor response.  Hydroxyurea did not improve leukocytosis.  The patient died within 2 weeks of treatment.",
      "study_design": "case report and literature review",
      "patient_population": "One 70-year-old female with CMML who developed severe pericardial effusion after an initially stable disease course.",
      "treatment_details": "Pericardiocentesis, intracardial mitoxantrone, and hydroxyurea were used. Systemic chemotherapy was not administered due to the patient's decreasing performance status.",
      "supporting_quotes": [
        "A case of a 70-year-old female with CMML is reported, who developed a severe pericardial effusion after an initially stable course of disease.",
        "She underwent pericardiocentesis and subsequent intracardial instillation of mitoxantrone with poor response.",
        "Leukocytosis did not respond to hydroxyurea.",
        "Because of decreasing performance status of the patient systemic chemotherapy was not applied and the patient died within 2 weeks."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 11077120 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/11077120/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Mora Elvira, Sanz Guillermo F Current management of patients with chronic myelomonocytic leukemia. Current opinion in oncology (2018)",
      "pmid": "30169461",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30169461/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "CMML is a heterogeneous disorder with variable natural course. Prognostic scoring systems are recommended for treatment tailoring. Somatic mutations impact survival but don't predict drug response.  Allogeneic hematopoietic cell transplantation is the only curative option, applicable to a minority. Higher-risk patients (MDS-like) are treated with HMAs, while those with myeloproliferative features receive hydroxyurea or HMAs, but these don't substantially change CMML's natural history.  Newer therapies are needed.",
      "study_design": "Review Article",
      "patient_population": "Patients with chronic myelomonocytic leukemia (CMML). The review discusses higher-risk patients displaying MDS-like characteristics and those with myeloproliferative features.",
      "treatment_details": "Higher-risk patients (MDS-like) are treated with hypomethylating agents (HMAs). Patients with myeloproliferative features generally receive hydroxyurea or HMAs.",
      "supporting_quotes": [
        "CMML is a heterogeneous malignant myeloid disorder sharing features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms and characterized by peripheral blood monocytosis and increased risk of progression to acute leukemia.",
        "Its natural course is highly variable and use of CMML-specific prognostic scoring systems is strongly recommended for tailoring treatment.",
        "Multiple recent studies have showed that somatic mutations, which are almost always present have a relevant and independent impact on survival but lack a clear role in predicting the response to currently available drugs.",
        "Allogeneic hematopoietic cell transplantation is the only curative option but is applicable to a minority of patients.",
        "Usually higher-risk patients displaying MDS-like characteristics are treated with hypomethylating agents (HMAs), whereas those with myeloproliferative features generally receive hydroxyurea or HMAs but none of these drugs substantially modify the natural history of CMML."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 30169461 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/30169461/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Lafargue Marie-Camille, Bobot Micka\u00ebl, Rennke Helmut G et al. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney international reports (2023)",
      "pmid": "38106568",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38106568/",
      "cmml_sample_size": 16,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "The two most frequent renal complications in CMML patients with kidney injury were lysozyme-induced nephropathy and renal infiltration by CMML.",
      "study_design": "retrospective multicenter study",
      "patient_population": "Patients with CMML and acute kidney injury (AKI), chronic kidney disease (CKD), or urine abnormalities.",
      "treatment_details": null,
      "supporting_quotes": [
        "Sixteen patients (males,  CONCLUSION: In this cohort of patients with CMML with a kidney injury, the 2 most frequent renal complications were lysozyme-induced nephropathy and renal infiltration by the CMML."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 38106568 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/38106568/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 24,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Bennett John M Chronic myelomonocytic leukemia. Current treatment options in oncology (2002)",
      "pmid": "12057067",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12057067/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Median survival for CMML patients is approximately 2 years. Hydroxyurea is the treatment of choice when the proliferative phase prevails. Allogeneic bone marrow transplantation should be considered for younger patients with high-risk CMML.  Overall therapeutic results are far from optimal.",
      "study_design": "Review Article",
      "patient_population": "Patients with CMML, median age 70 years.",
      "treatment_details": "Hydroxyurea for patients in the proliferative phase; allogeneic bone marrow transplant for younger high-risk patients; AML-type therapy followed by autologous stem cell or marrow transplant if a donor is unavailable.",
      "supporting_quotes": [
        "The median age of patients with CMML is 70 years; the median survival is approximately 2 years.",
        "When the proliferative phase prevails, hydroxyurea is the treatment of choice.",
        "For younger patients with high-risk CMML, an allogeneic bone marrow transplantation should be considered.",
        "If a donor cannot be identified, then combination acute myeloid leukemia-type therapy followed by an autologous stem cell or marrow transplant should be offered.",
        "Clinical trials should be considered if available because the overall results of therapeutic interventions are far from optimal."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 12057067 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/12057067/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Rezazadeh Alexandra, Deininger Michael, Atallah Ehab Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. Current treatment options in oncology (2023)",
      "pmid": "37300657",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37300657/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Hypomethylating agents are the mainstay of therapy but induce complete remissions in less than 20% of patients and do not prolong survival compared to hydroxyurea. Allogeneic stem cell transplant (ASCT) is potentially curative, but few patients qualify due to advanced age and/or comorbidities.",
      "study_design": "Review",
      "patient_population": "Chronic myelomonocytic leukemia (CMML) is a clonal hematologic malignancy of mostly older individuals that exhibits both myelodysplastic and myeloproliferative features. CMML presentation and outcome are variable, reflecting genetic and clinical heterogeneity.",
      "treatment_details": "Hypomethylating agents and hydroxyurea are mentioned as treatments.  Allogeneic stem cell transplant (ASCT) is also discussed as a potentially curative option.",
      "supporting_quotes": [
        "Hypomethylating agents are the mainstay of therapy but induce complete remissions in less than 20% of patients and do not prolong survival compared to hydroxyurea.",
        "Allogeneic stem cell transplant (ASCT) is potentially curative, but few patients qualify due to advanced age and/or comorbidities."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 37300657 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/37300657/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": null,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Gurung Shekhar, Karki Saurab, Khadka Manoj et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report. Annals of medicine and surgery (2012) (2023)",
      "pmid": "36845813",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
      "cmml_sample_size": 1,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "A 72-year-old male presented with CMML, characterized by leukocytosis, 22% monocytes, 17% blasts in bone marrow, and positive immunophenotyping markers.  Azacitidine was planned as treatment.",
      "study_design": "case report",
      "patient_population": "One 72-year-old male from Nepal with CMML.",
      "treatment_details": "Azacitidine, 7-day cycle for six cycles.",
      "supporting_quotes": [
        "Herein, the authors report a case of CMML in a 72-year-old male who presented with fever and abdominal pain for 2 days with a history of easy fatigability.",
        "Investigations showed leukocytosis with a monocyte count of 22% of white blood cell count, 17% blast cells in bone marrow aspiration, increased blast/promonocytes, and positive markers in immunophenotyping.",
        "The patient is planned for injection of azacitidine, 7 days cycle for a total of six cycles."
      ],
      "data_source_location": "Abstract and Case Presentation sections",
      "reference_note": "See PMID 36845813 - Abstract and Case Presentation sections",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/36845813/"
    },
    {
      "complete_response": null,
      "partial_response": null,
      "marrow_complete_response": null,
      "marrow_optimal_response": null,
      "pfs_median": null,
      "os_median": 36,
      "efs_median": null,
      "sae_frequency": null,
      "ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "non_ras_mutant_data": {
        "cr_rate": null,
        "pr_rate": null,
        "mcr_rate": null,
        "mor_rate": null,
        "os_median": null,
        "pfs_median": null,
        "efs_median": null,
        "sae_rate": null
      },
      "citation": "Itzykson Raphael, Fenaux Pierre, Solary Eric Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative? Best practice & research. Clinical haematology (2013)",
      "pmid": "24507815",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24507815/",
      "cmml_sample_size": null,
      "ras_mutant_sample_size": null,
      "non_ras_mutant_sample_size": null,
      "key_findings": "Median survival for CMML is 3 years (36 months).  Death is often due to progression to AML (20-30%) or cytopenias. ASXL1 mutation predicts outcome.",
      "study_design": "Review Article",
      "patient_population": "Patients diagnosed with CMML after age 50, with male predominance.  The abstract mentions CMML-1 and CMML-2 distinctions based on blast cell percentage.",
      "treatment_details": "Hydroxyurea is used in myeloproliferative forms; demethylating agents may be effective in aggressive forms. Allogeneic stem cell transplantation is a possibility but rarely feasible.",
      "supporting_quotes": [
        "Median survival is 3 years, with patients dying from progression to AML (20-30%) or from cytopenias.",
        "Hydroxyurea, which is the conventional cytoreductive agent, is used in myeloproliferative forms, and demethylating agents could be efficient in the most aggressive forms of the disease."
      ],
      "data_source_location": "Abstract",
      "reference_note": "See PMID 24507815 - Abstract",
      "verification_url": "https://pubmed.ncbi.nlm.nih.gov/24507815/"
    }
  ]
}